FEMY FEMASYS INC

NEUTRAL Impact: 4/10 8-K
Horizon days Filed Jun 4, 2026 Processed 1d 9h ago SEC 0001140361-26-023955
8-K context-dependent: Items 7.01
Latest settled — T+1d
FEMY ▼ -14.17% at T+1d
NEUTRAL call ✗ call lost -14.17% · α vs SPY -11.60% · entry $0.3570 → $0.3064
Next anchor: T+5d in 6d
Currently $0.3064 · -14.17% from $0.3570 entry
Entry anchored
Jun 3, 03:59 PM ET
via Databento tick
T+1d
-14.17%
call -14.17% · α -11.60%
$0.3064
settled 10h ago
T+5d
call — · α —
in 6d
T+20d
call — · α —
in 28d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Femasys announced a 1-for-20 reverse stock split effective June 5, 2026, with split-adjusted trading beginning June 8, 2026. The ticker symbol remains FEMY. This is a capital structure adjustment typically used to regain or maintain compliance with Nasdaq's minimum bid price listing requirement, though no specific compliance reason is stated in the filing.

Actionable Insight

Reverse split is a mechanical adjustment with no fundamental business change. Monitor for any Nasdaq compliance notice or subsequent capital markets activity (e.g., equity offering) that often follows reverse splits at micro-cap companies. The rounding-up of fractional shares creates a small, one-time beneficial effect for holders of odd lots.

Key Facts

  • 1-for-20 reverse stock split announced on June 4, 2026
  • Effective at 4:30 p.m. ET on June 5, 2026
  • Split-adjusted trading begins at market open on June 8, 2026
  • Ticker symbol FEMY unchanged
  • New CUSIP number: 31447E 204
  • Fractional shares rounded up to next whole share at DTC participant level

Financial Impact

No financial figures provided; reverse split reduces share count by 95% (20:1) but does not change market cap or enterprise value. No offering or capital raise associated.

sharesOutstandingstockPrice

Risk Factors

  • Reverse splits at micro-cap companies are often followed by dilutive offerings, which could pressure the stock
  • No stated compliance reason — if the split is to regain Nasdaq minimum bid price, failure to maintain it post-split could lead to delisting
  • Reduced liquidity from lower share count may increase volatility

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-023955
Document: 0001140361-26-023955-index-headers.html0001140361-26-023955
Document: 0001140361-26-023955-index.html0001140361-26-023955
Document: 0001140361-26-023955.txt0001140361-26-023955
5 reports for FEMY
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FEMY — sortable, filterable
Type Now
Jun 4, 2026
1d ago
8-K
NEUTRAL ★ 4/10
$0.3570 $0.3064▼ −14.17%▼ −11.60%$0.3064 (−14.17%)
May 13, 2026
23d ago
8-K
NEUTRAL ★ 3/10
awaiting T+1
May 8, 2026
28d ago
8-K
NEUTRAL ★ 4/10
$0.4040 $0.3770▼ −6.68%▼ −6.55%$0.3064 (−24.16%)
Apr 30, 2026
5w ago
DEFA14A
NEUTRAL ★ 2/10
$0.3840 $0.3720▼ −3.13%▼ −2.78%$0.3064 (−20.21%)
Mar 31, 2026
9w ago
8-K
BULLISH ★ 8/10
$0.4170 $0.4390▲ +5.28%▲ +5.20%$0.3064 (−26.52%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (39h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access